SUMMARY Diltiazem is a calcium slow-channel blocking drug that may be effective in the treatment of chronic stable angina pectoris. To evaluate the therapeutic efficacy 3 hours after a single oral dose of 120 mg, 12 men with chronic stable angina pectoris performed a maximal exercise test on a bicycle ergometer after ingesting either placebo or diltiazem administered in a double-blind fashion. During submaximal exercise at a fixed work load, diltiazem decreased the average heart rate response from 119 ± 17 to 107 ± 14 beats/ min (p < 0.01), systolic blood pressure from 182 ± 15 to 175 ± 15 mm Hg (p < 0.05) and the rate-pressure product from 21.8 ± 4.2 to 18.8 ± 3.2 x 10-3 units (p < 0.01). The average submaximal work load at which significant ST-segment depression (0.1 mV) first appeared was increased from 355 ± 142 to 525 + 143 seconds (p < 0.01) after diltiazem. At peak exercise after diltiazem, the average depth of ST-segment depression in any one lead and the extent of myocardial ischemia observed in all 12 ECG leads were decreased (p < 0.01), even though the average work load was increased by 29% (p < 0.01). Peak heart rate, systolic blood pressure and rate-pressure product were similar with placebo and diltiazem. The plasma diltiazem concentration was 139 ± 29 ng/ml 3 hours after ingestion and was significantly (p < 0.05) related to the increased time to the onset of important ST-segment depression (r = 0.65) and to the decrease in the extent of myocardial ischemia observed in all 12 ECG leads (r = -0.61) compared with placebo. Thus, diltiazem is effective in treating chronic stable angina pectoris. It decreases myocardial oxygen requirements during upright exercise and appears to increase myocardial oxygen delivery.
THE EFFECTIVENESS of diltiazem, a calcium slowchannel blocking drug, in the prevention of coronary spasm is well documented.' It decreases systemic arteriolar resistance, increases coronary artery blood flow and has a negative chronotropic effect.t fThese properties have justified its study in the treatment of exertional angina in patients with fixed coronary artery stenoses.]-1' Repeat oral-dose studies of diltiazem show an increase in the time to the onset of angina or to significant ST-segment depression during standard multistage exercise testing.7-9 Both the total daily dose and schedule appear to influence the drug's efficacy and ability to reduce indexes of myocardial oxygen demand during exercise. Hossack and Bruce7 found a greater effect using 60 mg four times daily than smaller doses and with a schedule of 30 mg four times daily vs 60 mg three times daily. Single-dose studies'0 " with 60 and 90 mg of diltiazem have not shown a significant decrease in the indexes of myocardial oxygen demand during exercise.
Therefore, in the present study, we compared, after 3 hours, the effects of a single oral dose of 120 mg of diltiazem vs placebo on the time to the onset of significant ST-segment depression (0.1 mV) and to peak exercise; the indexes of myocardial oxygen consumption at a fixed submaximal work load, at the onset of significant ST-segment depression and at peak exercise; and the extent of electrocardiographic ischemia at peak exercise. Finally, when diltiazem resulted in significant improvements in the above mentioned variables, correlations were determined with the plasma diltiazem concentration measured 3 hours after ingestion.
Methods

Patient Population
Twelve men, mean age 58 years (range 45-64 years), who were treated for chronic stable angina pectoris formed the study group. None of the patients had rest angina. Two patients had had a previous inferior wall myocardial infarction. Each patient had ¢ 0.1 mV of horizontal or downsloping ST-segment depression for 0.08 second after the J point on multistage bicycle ergometer testing. Coronary angiography, performed in 10 patients, revealed significant fixed stenoses ¢ 70% of at least one major artery. Three patients had one-, five two-and two three-vessel disease. Five patients had an abnormal left ventricular contraction pattern. Patients who had severe hypertension, intraventricular conduction disturbances, significant ventricular dysrhythmia and hepatic or renal dysfunction were excluded. The purpose of the study and possible side effects of diltiazem were explained, and each patient gave informed consent.
Experimental Protocol
A baseline multistage bicycle ergometer exercise test was used to familiarize participants with the laboratory conditions. After at least 48 hours, the patients returned to the laboratory in the morning on two occasions separated by [3] [4] [5] [6] [7] days. In the intervening period, the patients took isosorbide dinitrate until 24 obtained by sphygmomanometry. The heart rate, systolic blood pressure and rate-pressure product were studied at rest, at the onset of 0.1 mV of exercise-induced horizontal or downsloping ST-segment depression, 2. 13 and in the 10 seconds preceding the termination of the test. The ST segment was measured using a seven-power magnifying glass calibrated in tenths of a millimeter and by an investigator with no knowledge of the treatment received. At peak exercise, the ST segment was evaluated in each ECG lead. The amount of ST-segment depression in three consecutive complexes for each lead was averaged and the sum of the averaged beats was used to determine the extent of electrocardiographic ischemia. After exercise, a venous blood sample was withdrawn in a heparinized tube and rapidly centrifuged. The plasma was stored at -30°C and diltiazem blood concentrations were then determined for each patient using the fluoroscopic method of Rovei et al. '4 Statistical Analysis Statistical comparisons of differences between placebo and diltiazem treatments were made using either the t test for paired data or a repeated-measures analysis of variance with the Tukey test'5 16 2) . At peak exercise, the average heart rate, CIRCULATION 24 DILTIAZEM AND MYOCARDIAL ISCHEMIA/Wagniart et al. Three hours after diltiazem, we observed a reduction in heart rate, systolic blood pressure, rate-pressure product and ECG evidence of myocardial ischemia during exercise at a fixed submaximal work load. A significant decrease in the indexes of myocardial oxygen demand was not found in the studies using a single dose of 6011 or 90 mg, 10 and repeat dose studies showed little or no effect at doses of less than 240 mg/day.7-9 A lower rate-pressure product at a constant work load in patients with chronic stable angina pectoris has also been reported for other slow-channel calcium inhibitors such as verapamil'7 and nifedipine,8-20 although with nifedipine there was either a reduction in systolic blood pressure alone"8 19 or combined with a small decrease in heart rate. 20 The differing results obtained in exercise studies of slow-channel calcium inhibitors may be due to different dose levels and schedules used in the individual studies or to the specific action of each drug. The average 3-hour plasma diltiazem concentration reported in the present study is within the range of clinically effective drug levels.2' The importance of the quantity of the oral dose can be surmised from the data of Hossack and Bruce,7 who found a progressive increase in exercise capacity with larger and more frequent doses (four times daily vs three times daily). Peak plasma diltiazem levels are dose-related and are reached in 3-4 hours, 21 with maximal hemodynamic responses occurring 2-3 hours after oral ingestion. 22 The lower heart rate response during submaximal exercise after diltiazem ingestion is not unlike the exercise response observed in patients taking ,3 blockers.23
There is a dose-related suppression of sinoatrial node activity with calcium-channel blockers.6 However, unlike diltiazem, the more potent vasodilator and reflex /3-adrenergic response of nifedipine24 can reduce or abolish this negative chronotropic effect. '8-20 Indirect Evidence for Improved Myocardial Oxygen Supply Diltiazem delayed the onset of exercise-induced STsegment depression (355 to 525 seconds). The ratepressure product at this threshold was higher than with placebo, which might be attributable to a depression of myocardial contractility, a smaller increase in ventricular volumes, or an improved myocardial perfusion. The negative inotropic effect of diltiazem is reported to be minor, 26 and less than that with nifedipine27 or verapamil.27 28 A smaller ischemia-induced increase in 26 CIRCULATION DILTIAZEM AND MYOCARDIAL ISCHEMIAIWagniart et al. 
